Contineum Therapeutics has shared topline results from its Phase 2 VISTA trial of PIPE-307, an oral M1 receptor antagonist being developed for relapsing-remitting multiple sclerosis (RRMS). The short version: safety looked fine, efficacy did not pan out.
Let’s break it down.
What the VISTA Trial Set Out to Test
This was a randomized, double-blind, placebo-controlled proof-of-concept study.
The goal: see whether PIPE-307 could improve vision-related outcomes and other RRMS measures.
Key design features:
- Multi-centre Phase 2 trial
- Two dose levels
- Clinical and imaging endpoints
- Primary endpoint focused on binocular 2.5% low-contrast letter acuity
What Actually Happened
Safety
Both PIPE-307 doses showed acceptable safety and tolerability. No major surprises.
Efficacy
The trial did not meet the:
- Primary endpoint
- Secondary efficacy endpoints
Patients on PIPE-307 did not show meaningful improvement in low-contrast vision scores compared to placebo. The team is still analyzing exploratory endpoints for deeper insights.
What Contineum Says About the Results?
Dr. Timothy Watkins, CMO and Head of Development, captured the mood directly:
“We’re disappointed by these results… We intend to learn from these data and remain committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.”
This is a candid admission paired with a clear commitment to ongoing R&D—something rare and refreshing.
What Happens Next?
- Contineum plans to present the full dataset at an upcoming medical meeting.
- A peer-reviewed publication will follow.
- The company continues advancing its broader pipeline in neuroinflammatory and neurodegenerative (NI&I) diseases.
PIPE-307 may not have delivered the clinical signal they hoped for, but the program adds valuable scientific data to a high-need therapeutic area.
About Contineum Therapeutics
Contineum is a clinical-stage biotech focused on novel, oral small-molecule therapies for conditions with significant unmet medical needs. Multiple internally developed candidates are now in clinical trials.
